Legislators introduce bill to reverse CMS decision on ESA coverage
Battle over ESA coverage continues
Federal lawmakers are presenting a united front in their battle to save Medicare reimbursements for anemia drugs. Reps. Anna Eshoo (D, Calif.) and Mike Rogers (R, Mich.) have introduced a bill to reverse a CMS decision to restrict reimbursements to low-dose levels of erythropoiesis-stimulating agents (ESAs). Thedecision, issued in July, limits the duration of ESA treatment to a maximum of eight weeks after a chemotherapy session and requires doctors to wait until hemoglobin levels drop below 10 gm/dl before starting ESA treatment. The restrictions have come under fire from several groups, including the
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
